Literature DB >> 25832691

Magnetic resonance imaging assessment of spinal cord and cauda equina motion in supine patients with spinal metastases planned for spine stereotactic body radiation therapy.

Chia-Lin Tseng1, Marshall S Sussman2, Eshetu G Atenafu3, Daniel Letourneau4, Lijun Ma5, Hany Soliman6, Isabelle Thibault6, B C John Cho4, Anna Simeonov4, Eugene Yu2, Michael G Fehlings7, Arjun Sahgal8.   

Abstract

PURPOSE: To assess motion of the spinal cord and cauda equina, which are critical neural tissues (CNT), which is important when evaluating the planning organ-at-risk margin required for stereotactic body radiation therapy. METHODS AND MATERIALS: We analyzed CNT motion in 65 patients with spinal metastases (11 cervical, 39 thoracic, and 24 lumbar spinal segments) in the supine position using dynamic axial and sagittal magnetic resonance imaging (dMRI, 3T Verio, Siemens) over a 137-second interval. Motion was segregated according to physiologic cardiorespiratory oscillatory motion (characterized by the average root mean square deviation) and random bulk shifts associated with gross patient motion (characterized by the range). Displacement was evaluated in the anteroposterior (AP), lateral (LR), and superior-inferior (SI) directions by use of a correlation coefficient template matching algorithm, with quantification of random motion measure error over 3 separate trials. Statistical significance was defined according to P<.05.
RESULTS: In the AP, LR, and SI directions, significant oscillatory motion was observed in 39.2%, 35.1%, and 10.8% of spinal segments, respectively, and significant bulk motions in all cases. The median oscillatory CNT motions in the AP, LR, and SI directions were 0.16 mm, 0.17 mm, and 0.44 mm, respectively, and the maximal statistically significant oscillatory motions were 0.39 mm, 0.41 mm, and 0.77 mm, respectively. The median bulk displacements in the AP, LR, and SI directions were 0.51 mm, 0.59 mm, and 0.66 mm, and the maximal statistically significant displacements were 2.21 mm, 2.87 mm, and 3.90 mm, respectively. In the AP, LR, and SI directions, bulk displacements were greater than 1.5 mm in 5.4%, 9.0%, and 14.9% of spinal segments, respectively. No significant differences in axial motion were observed according to cord level or cauda equina.
CONCLUSIONS: Oscillatory CNT motion was observed to be relatively minor. Our results support the importance of controlling bulk patient motion and the practice of applying a planning organ-at-risk margin.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25832691     DOI: 10.1016/j.ijrobp.2014.12.037

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  13 in total

1.  The era of stereotactic body radiotherapy for spinal metastases and the multidisciplinary management of complex cases.

Authors:  Rachit Kumar; Anick Nater; Ahmed Hashmi; Sten Myrehaug; Young Lee; Lijun Ma; Kristin Redmond; Simon S Lo; Eric L Chang; Albert Yee; Charles G Fisher; Michael G Fehlings; Arjun Sahgal
Journal:  Neurooncol Pract       Date:  2015-07-27

2.  Spinal metastasis: diagnosis, management and follow-up.

Authors:  Mahmud Mossa-Basha; Peter C Gerszten; Sten Myrehaug; Nina A Mayr; William Tc Yuh; Pejman Jabehdar Maralani; Arjun Sahgal; Simon S Lo
Journal:  Br J Radiol       Date:  2019-07-25       Impact factor: 3.039

3.  Nonlocal Means Denoising of Self-Gated and k-Space Sorted 4-Dimensional Magnetic Resonance Imaging Using Block-Matching and 3-Dimensional Filtering: Implications for Pancreatic Tumor Registration and Segmentation.

Authors:  Jun Jin; Elizabeth McKenzie; Zhaoyang Fan; Richard Tuli; Zixin Deng; Jianing Pang; Benedick Fraass; Debiao Li; Howard Sandler; Guang Yang; Ke Sheng; Shuiping Gou; Wensha Yang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-06       Impact factor: 7.038

Review 4.  Stereotactic body radiotherapy for benign spinal tumors: Meningiomas, schwannomas, and neurofibromas.

Authors:  Lindsay Hwang; Christian C Okoye; Ravi B Patel; Arjun Sahgal; Matthew Foote; Kristin J Redmond; Christoph Hofstetter; Rajiv Saigal; Mahmud Mossa-Basha; William Yuh; Nina A Mayr; Samuel T Chao; Eric L Chang; Simon S Lo
Journal:  J Radiosurg SBRT       Date:  2019

Review 5.  Radiation myelopathy following stereotactic body radiation therapy for spine metastases.

Authors:  Wee Loon Ong; Shun Wong; Hany Soliman; Sten Myrehaug; Chia-Lin Tseng; Jay Detsky; Zain Husain; Pejman Maralani; Lijun Ma; Simon S Lo; Arjun Sahgal
Journal:  J Neurooncol       Date:  2022-06-23       Impact factor: 4.506

6.  The Restless Spinal Cord in Degenerative Cervical Myelopathy.

Authors:  M Hupp; N Pfender; K Vallotton; J Rosner; S Friedl; C M Zipser; R Sutter; M Klarhöfer; J M Spirig; M Betz; M Schubert; P Freund; M Farshad; A Curt
Journal:  AJNR Am J Neuroradiol       Date:  2021-02-04       Impact factor: 3.825

7.  Variability in spine radiosurgery treatment planning - results of an international multi-institutional study.

Authors:  André Toussaint; Anne Richter; Frederick Mantel; John C Flickinger; Inga Siiner Grills; Neelam Tyagi; Arjun Sahgal; Daniel Letourneau; Jason P Sheehan; David J Schlesinger; Peter Carlos Gerszten; Matthias Guckenberger
Journal:  Radiat Oncol       Date:  2016-04-18       Impact factor: 3.481

8.  Spine Stereotactic Body Radiotherapy: Indications, Outcomes, and Points of Caution.

Authors:  Chia-Lin Tseng; Wietse Eppinga; Raphaele Charest-Morin; Hany Soliman; Sten Myrehaug; Pejman Jabehdar Maralani; Mikki Campbell; Young K Lee; Charles Fisher; Michael G Fehlings; Eric L Chang; Simon S Lo; Arjun Sahgal
Journal:  Global Spine J       Date:  2017-04-06

Review 9.  Stereotactic spine radiosurgery: Review of safety and efficacy with respect to dose and fractionation.

Authors:  Michael Huo; Arjun Sahgal; David Pryor; Kristin Redmond; Simon Lo; Matthew Foote
Journal:  Surg Neurol Int       Date:  2017-02-20

10.  Positional Accuracy of Treating Multiple Versus Single Vertebral Metastases With Stereotactic Body Radiotherapy.

Authors:  Joe H Chang; Arnjeet Sangha; Derek Hyde; Hany Soliman; Sten Myrehaug; Mark Ruschin; Young Lee; Arjun Sahgal; Renee Korol
Journal:  Technol Cancer Res Treat       Date:  2016-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.